Cosmetic cross-reference

Lutein

CAS 127-40-2

Lutein (CAS 127-40-2) is a Phase 3 pharmaceutical compound with 1 bioactivity target and 1,157 adverse event associations.

SOURCE NLM DailyMed

Label records

SOURCE EMBL-EBI ChEMBL

Bioactivity

SOURCE DrugCentral

Adverse signals

1,157

SOURCE IUPHAR/BPS

PubMed IDs

SOURCE EMBL-EBI ChEMBL B25820EEF0F0

Compound Identity

Matched identifiers and naming fields for the pharmaceutical compound record.

Primary Name

Lutein

CAS Number

127-40-2

UNII

X72A60C9MT

InChIKey

KBPHJBAIARWVSC-RGZFRNHPSA-N

ChEMBL ID

CHEMBL173929

Molecule Type

Small molecule

Source Match

EMBL-EBI ChEMBL (INCHIKEY)

natural product

SOURCE EMBL-EBI ChEMBL B25820EEF0F0

Clinical Development Phase

Highest clinical development phase rendered from the matched compound identifier rows.

Phase 3

Late-stage clinical development phase from the compound identifier source.

ChEMBL CHEMBL173929 | Small molecule

SOURCE Ingredients table / CosIng profile same-CAS cross-reference

Cross-Reference to Cosmetics

Same-CAS ingredient record found in the cosmetics vertical.

This substance also has a cosmetic safety profile →

SOURCE EMBL-EBI ChEMBL 1 bioactivity row

Bioactivity & Target Interactions

Target-level activity records with assay counts, activity type, and measured value where present.

Target	Activity	Value	Assays	Organism
-	Potency	25863.75 nM	2	-

SOURCE DrugCentral 23 associations

Adverse Event Associations

DrugCentral / FAERS disproportionality signal rows matched to this compound.

Reaction PT	Drug AE	LLR	MedDRA
Appendicolith	39	131.186	10074458
Blood phosphorus increased	37	113.469	10050196
Appendicitis	40	96.225	10003011
Ventricular fibrillation	41	84.275	10047290
Cardiogenic shock	39	69.328	10007625
Stress	50	64.601	10042209
Myasthenia gravis	23	58.269	10028417
Blood uric acid increased	24	55.514	10005861
Abdominal distension	52	51.187	10000060
Dry mouth	45	48.906	10013781
Ascites	40	46.399	10003445
Constipation	73	38.672	10010774
Macular degeneration	21	33.754	10025409
Hyponatraemia	48	32.632	10021036
Multiple organ dysfunction syndrome	39	31.495	10077361
Somnolence	53	23.784	10041349
Full blood count decreased	19	22.64	10017413
Incorrect route of product administration	20	22.614	10081202
Fall	80	22.37	10016173
Hyperphosphataemia	10	22.361	10020711
Analgesic therapy	6	21.341	10053469
Sleep disorder therapy	6	21.219	10040990
Drug therapy	6	20.259	10063370

Association rows are source-linked signal records, not incidence rates or clinical causality claims.

SOURCE NLM RxNorm 1 name row

Drug Names / RxNorm

Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.

Name	RxCUI	Type	Source
lutein	11359	IN	RXNORM

SOURCE Rendered pharma page rows FAQPage JSON-LD

Frequently Asked Questions

Short answers generated only from the same visible source-linked rows on this page.

What is Lutein used for in pharmaceutical contexts?

Lutein (CAS 127-40-2) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.

What are the known adverse events for Lutein?

Lutein has 1,157 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Appendicolith, Blood phosphorus increased, Appendicitis, Ventricular fibrillation, Cardiogenic shock. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.

Is Lutein also used in cosmetics?

Yes. The ingredients table has a same-CAS cosmetic profile for Xanthophylls with EU status "permitted".

What clinical phase is Lutein in?

Lutein is rendered with ChEMBL max phase 3.